Shares of NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) hit a new 52-week high during mid-day tr

Valuation Assessment of NeoGenomics Inc (NEO)On August 26, 2026, NeoGenomics Inc (NEO) shares rose 3

New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testi

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST M

Greenland Mines released an Initial Assessment for its Sarfartoq project, projecting a pre-tax net p

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take

Phase 2a results showed 48.9% six-month progression-free survival versus a 20% historical benchmark,

Company to request a Type B meeting with the FDA to align on a registrational path in a setting with

Neo Performance Materials TSE: NEO reported record second-quarter results, citing higher volumes, fa

NeOnc (Nasdaq: NTHI) will host an investor conference call and webcast on Wednesday, August 12, 2026

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take

On July 31, 2026, NeoGenomics Inc (NEO) shares fell 3.7% to $15.29, reflecting a mixed price perform

NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) reached a new 52-week high on Wednesday after the

Gainers Autonomix Medical (NASDAQ:AMIX) shares increased by 89.4% to $5.21 during Wednesday's r

Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday&#39

Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price ta

NeoGenomics NASDAQ: NEO raised its full-year 2026 revenue and adjusted EBITDA guidance after reporti

NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $797.000 million-$803.000 million to $802.

NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.05 per share which beat the analyst conse

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period e

American Capital Management Inc. lowered its position in shares of NeoGenomics, Inc. (NASDAQ: NEO) b

Benchmark analyst Bruce D. Jackson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the p

FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification a

FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approac

NeoGenomics, Inc. (the "Company") (NASDAQ:NEO), a leading provider of oncology diagnostic so

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (the “Company”) (NASDAQ: NEO), a leading provid

CALABASAS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI

Available within NEO PanTracer™ Pro for prostate cancer and as a standalone test, PTEN IHC CDx ident

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PTEN IHC CDx, the first IHC companion diagno

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2026 financial results

In addition, NeoGenomics granted the initial purchasers of the notes an option to purchase, for sett

solutions that enable precision medicine, announced today that it has commenced a private offering o

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable prec

Benchmark analyst Bruce Jackson upgrades NeoGenomics (NASDAQ:NEO) from Hold to Buy and announces

TD Cowen analyst Dan Brennan maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price t

Leerink Partners analyst Puneet Souda upgrades NeoGenomics (NASDAQ:NEO) from Market Perform to Ou

NeoGenomics (NASDAQ:NEO) raises FY2026 sales outlook from $793.000 million-$801.000 million to $797.

NeoGenomics (NASDAQ:NEO) reported quarterly earnings of $0.01 per share which met the analyst consen

Through this integration, physicians can order NeoGenomics' comprehensive suite of tests, spanni

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable prec

Piper Sandler analyst David Westenberg maintains NeoGenomics (NASDAQ:NEO) with a Overweight and r

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable prec